Molecular testing is usually performed for EGFR and ALK mutations but other markers such as KRAS, ROS1, BRAF and MET mutations can be tested and, within clinical studies, medications are available [6 8].
This is caused by different features of the markers, such as mutation rates and the biased migration between organelle (pollen migration) and nuclear markers (pollen migration and seed migration, seed migration is very little).
The identification of quantitative models f linking biological stress factors and molecular markers, such as mutations on the genome, with macroscopic biomedical phenotypes plays a crucial role for a broad range of applications in biomedicine.
Thirty-five to 50 percent of patients have a normal karyotype, and molecular markers, such as mutations in FLT3, CEBPα, and NMP1, further stratify this large group.
Although many possible biological markers such as mutations of p53 and k-ras genes have been reported, none of them has been established as a marker in decision-making of the treatment of NSCLC.
Currently, targeted therapies have progressed rapidly, based upon the discovery of novel molecular markers such as mutations in EGFR (epidermal growth factor receptor), KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) genes and ALK (anaplastic lymphoma kinase) rearrangements [ 3- 5], however, the overall progression-free survival rate of lung cancer patients is still suboptimal [ 6].
Also, our aim was to characterize SSTR2 expression in HGGs in relation to prognostic markers such as IDH1 mutation.
Therefore, there is an incentive to define biomarkers of response to therapy, such as mutation status or, perhaps, more encompassing markers such as those indicating AMPK activity.
Molecular epidemiology markers, such as TP53 mutation profile can help to better identify aetiological agents and mechanisms related to early neoplastic transformation of the oesophageal mucosa.
We found that high MnSOD expression evidently correlated with advanced tumor grade, and overlapped with other poor prognostic markers such as p53 mutation as well as negative status of estrogen receptor (ER) and progesterone receptor (PgR).
